Global AAV Vector Gene Therapy Supply, Demand and Key Producers, 2023-2029

Global AAV Vector Gene Therapy Supply, Demand and Key Producers, 2023-2029

The global AAV Vector Gene Therapy market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

AAV (Adeno-Associated Virus) vector gene therapy is a gene therapy method that uses adeno-associated virus as a vector to deliver, express or repair specific genes in patients. AAV is a non-pathogenic, non-oncogenic virus that is widely used in gene therapy research and clinical trials.

This report studies the global AAV Vector Gene Therapy production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for AAV Vector Gene Therapy, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of AAV Vector Gene Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global AAV Vector Gene Therapy total production and demand, 2018-2029, (K Units)

Global AAV Vector Gene Therapy total production value, 2018-2029, (USD Million)

Global AAV Vector Gene Therapy production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global AAV Vector Gene Therapy consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: AAV Vector Gene Therapy domestic production, consumption, key domestic manufacturers and share

Global AAV Vector Gene Therapy production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global AAV Vector Gene Therapy production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global AAV Vector Gene Therapy production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global AAV Vector Gene Therapy market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include uniQure, Roche, Novartis, BioMarin Pharmaceutical, Ferring Pharmaceuticals A/S, CSL Behring LLC, PTC Therapeutics, Inc. and Pfizer Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World AAV Vector Gene Therapy market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global AAV Vector Gene Therapy Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global AAV Vector Gene Therapy Market, Segmentation by Type
AAV1
AAV2
AAV8
Other

Global AAV Vector Gene Therapy Market, Segmentation by Application
Duchenne Dystrophy
Hemophilia
Retinal Diseases
Other

Companies Profiled:
uniQure
Roche
Novartis
BioMarin Pharmaceutical
Ferring Pharmaceuticals A/S
CSL Behring LLC
PTC Therapeutics, Inc.
Pfizer Inc.

Key Questions Answered

1. How big is the global AAV Vector Gene Therapy market?

2. What is the demand of the global AAV Vector Gene Therapy market?

3. What is the year over year growth of the global AAV Vector Gene Therapy market?

4. What is the production and production value of the global AAV Vector Gene Therapy market?

5. Who are the key producers in the global AAV Vector Gene Therapy market?